Profile data is unavailable for this security.
About the company
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-39.35m
- Incorporated2019
- Employees29.00
- LocationElevation Oncology Inc101 Federal Street, Suite 1900BOSTON 02110United StatesUSA
- Phone+1 (716) 371-1125
- Fax+1 (302) 697-4597
- Websitehttps://elevationoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 148.15m | 22.00 | -- | 1.64 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| ProQR Therapeutics NV | 14.75m | -29.36m | 149.29m | 157.00 | -- | 4.06 | -- | 10.12 | -0.3616 | -0.3616 | 0.1817 | 0.452 | 0.0957 | -- | -- | 93,960.41 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Invivyd Inc | 0.00 | -206.82m | 150.34m | 94.00 | -- | 0.8416 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| CervoMed Inc | 9.49m | -593.84k | 152.20m | 8.00 | 9.34 | 21.32 | -- | 16.03 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 153.00m | 5.00 | -- | 3.86 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 153.33m | 101.00 | -- | 8.26 | -- | 5.66 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 156.20m | 179.00 | -- | 0.6676 | -- | 1.60 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 157.48m | 65.00 | -- | 1.52 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 157.90m | 29.00 | -- | 1.97 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 158.13m | 107.00 | -- | 0.6555 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 160.03m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Quantum-Si Inc | 1.29m | -91.82m | 164.51m | 159.00 | -- | 0.6483 | -- | 128.02 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 166.54m | 112.00 | -- | -- | -- | 7.58 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 166.90m | 22.00 | -- | 3.37 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
Data as of Jul 19 2024. Currency figures normalised to Elevation Oncology Inc's reporting currency: US Dollar USD
50.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 31 Mar 2024 | 3.89m | 7.11% |
| Point72 Asset Management LPas of 31 Mar 2024 | 3.37m | 6.17% |
| Tang Capital Management LLCas of 31 Mar 2024 | 3.06m | 5.60% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 3.06m | 5.59% |
| Empery Asset Management LPas of 31 Dec 2023 | 2.84m | 5.20% |
| Aisling Capital Management LPas of 31 Mar 2024 | 2.83m | 5.19% |
| Braidwell LPas of 31 Mar 2024 | 2.38m | 4.35% |
| Darwin Global Management Ltd.as of 31 Mar 2024 | 2.33m | 4.27% |
| BVF Partners LPas of 31 Mar 2024 | 2.31m | 4.23% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.55m | 2.84% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
